SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23810379.
- Also identified by DOI 10.1016/j.ajhg.2013.05.023 and PMC identifier 3710758.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The phosphatidylinositol 3 kinase (PI3K) pathway regulates fundamental cellular processes such as metabolism, proliferation, and survival. A central component in this pathway is the p85α regulatory subunit, encoded by PIK3R1. Using whole-exome sequencing, we identified a heterozygous PIK3R1 mutation (c.1945C>T [p.Arg649Trp]) in two unrelated families affected by partial lipodystrophy, low body mass index, short stature, progeroid face, and Rieger anomaly (SHORT syndrome). This mutation led to impaired interaction between p85α and IRS-1 and reduced AKT-mediated insulin signaling in fibroblasts from affected subjects and in reconstituted Pik3r1-knockout preadipocytes. Normal PI3K activity is critical for adipose differentiation and insulin signaling; the mutated PIK3R1 therefore provides a unique link among lipodystrophy, growth, and insulin signaling.
Medical subject headings
- Class Ia Phosphatidylinositol 3-Kinase
- Growth Disorders
- Hypercalcemia
- Metabolic Diseases
- Nephrocalcinosis
- Signal Transduction